Evommune Initiates Phase 2b Trial of its Oral MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Atopic Dermatitis August 27, 2025
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update August 15, 2025
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update August 15, 2025
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update August 13, 2025
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease August 13, 2025
